Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy vs. Darunavir/Ritonavir with Two Nucleoside Reverse Transcriptase Inhibitors in the PROTEA Trial - Sorbonne Université
Article Dans Une Revue HIV medicine Année : 2017

Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy vs. Darunavir/Ritonavir with Two Nucleoside Reverse Transcriptase Inhibitors in the PROTEA Trial

Dates et versions

hal-03703933 , version 1 (24-06-2022)

Identifiants

Citer

Pm Girard, A Antinori, J. R. Arribas, D Ripamonti, C Bicer, et al.. Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy vs. Darunavir/Ritonavir with Two Nucleoside Reverse Transcriptase Inhibitors in the PROTEA Trial. HIV medicine, 2017, 18 (1), pp.5--12. ⟨10.1111/hiv.12386⟩. ⟨hal-03703933⟩
10 Consultations
0 Téléchargements

Altmetric

Partager

More